Tau levels fall, cognitive decline slows down with diranersen

Patients with early Alzheimer’s disease treated with diranersen experienced slower cognitive decline and greater reductions in tau compared with placebo, according to data presented at the Alzheimer’s Association International Conference.Diranersen (BIIB080, Biogen) is an investigational antisense oligonucleotide therapy that reduces tau production by targeting microtubule-associated